CTOs on the Move

Glyscend

www.glyscend.com

 
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.glyscend.com
  • 1812 Ashland Avenue Suite 110
    Baltimore, MD USA 21205
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Glyscend raised $20.5M on 06/11/2020

Similar Companies

Applied Biosystems by Life Technologies

AXYS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, design and development of therapeutic small molecules that address significant markets with major unmet medical needs. AXYS collaborates with large pharmaceutical

Axiom Real-time Metrics

Axiom Real-time Metrics is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuron Therapeutics

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company`s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.

Koniku

The future is different. We are building sensing and thinking machines, with synthetic neurobiology at its core. Machines with extremely dense sensing and computation based on carbon. In our systems, everything can be engineered with care for sustainab...

Acasti Pharma

Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. To carry out this mission, Acasti is advancing its portfolio of bioactive ingredients, by purifying and concentrating krill-oil extracts through innovative technology, to produce products targeting the prescription drug and medical food markets.